Minute Insight: Inivata's RaDaR Assay Study Yields Encouraging Results
RaDaR, a test for head and neck squamous cell carcinoma, demonstrated high efficacy in a new study.
You may also be interested in...
Hedera DX’s liquid biopsy test uses machine learning to recommend drugs to patients based on a tumor’s circulating DNA profile.
Inivata will remain a separate liquid biopsy division alongside NeoGenomics’ growing clinical, pharma and informatics divisions.
Dexcom has expanded the availability of its G7 sensor to five new markets, including the UK and Germany. FDA approval in the US has been delayed by software changes.